LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma
Phase of Trial: Phase II/III
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Registrational; Therapeutic Use
- Acronyms LUME-Meso
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 30 Jun 2019 Trial has been completed in Croatia, according to European Clinical Trials Database record.
- 15 Mar 2019 Status changed from completed to discontinued.
- 28 Feb 2019 The trial has been Discontinued in Netherlands (End Date; 2018-07-17).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History